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Is Time of Renal Hypoperfusion an
Important Variable in Determining
Response to Renal Artery
Revascularization?
The CORAL (Cardiovascular Outcomes in Renal Atherosclerotic
Lesions) trial found that stent implantation did not provide any
beneﬁt beyond optimal medical therapy in the occurrence of death or
adverse cardiovascular or renal events in patients with moderately
severe atherosclerotic renal artery stenosis (1). There was a modest,
consistent difference in systolic blood pressure favoring the stent
group, but this did not result in a decrease in adverse clinical out-
comes. These ﬁndings are consistent with the ASTRAL (Angio-
plasty and Stenting for Renal Atherosclerotic Lesions) trial (2) and
the STAR (Stent Placement and Blood Pressure and Lipid-
Lowering for the Prevention of Progression of Renal Dysfunction
CausedbyAtheroscleroticOstial Stenosis of theRenalArtery) trial (3).
Over the years, studies of renal artery intervention have been
criticized for small sample size, the use of angioplasty alone rather
than stenting, high treatment-crossover rate, and enrollment of
patients with renal artery lesions that were not hemodynamically
signiﬁcant. CORAL is the largest study of renal artery intervention
and anticipated all of these potential criticisms. Even though the
threshold for enrollment in CORAL was lowered to include ste-
nosis of 60%, a subgroup analysis limited to patients with
stenosis 80% did not show any beneﬁt to stent implantation.
Why have the clinical trials of stenting of atherosclerotic renal
artery stenosis failed to show improved clinical outcomes? One var-
iable that might play an important role in determining the beneﬁt of
revascularization is the time of renal hypoperfusion. In the 2-kidney-
1-clip model, abrupt onset of decreased renal perfusion is associated
with renin-angiotensin system activation, leading to sodium and
water retention. Over time, the renin-angiotensin system returns to
baseline levels and the intact normal kidney compensates to excrete
sodium and water by pressure natriuresis (4). Transient activationof the renin-angiotensin system leads to elevated oxidative stress,
sympathoadrenergic activation, and impaired vasoactive responses
within both the kidney and the systemic microcirculation (5).
Moreover, animal studies show that persistent ischemia leads to
irreversible kidney damage and development of a chronic kidney
disease phenotype (6). Similar renal damage is seen in humans; the
majority of patients with renal artery stenosis have renal parenchymal
changes including interstitial ﬁbrosis, tubular atrophy, glomerulo-
sclerosis, periglomerular ﬁbrosis, and a variety of arteriolar abnor-
malities (7). Finally, there is evidence that short-term elevation in
angiotensin II levels can accelerate the development of atherosclerosis
and lead to changes in the arterial wall that persist even after angio-
tensin levels return to baseline (8,9). It is unclear to what extent, if
any, that these adverse renal and vascular effects respond to
revascularization.
Data from animal models suggest that renal parenchymal
damage and aortic atherosclerotic changes begin soon after renal
hypoperfusion. These effects worsen over time and many of the
changes are irreversible. Further studies are needed to determine
whether there is a “window of time” in humans during which
revascularization is beneﬁcial and whether it can be identiﬁed with
biomarkers or renal imaging.
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